0001214659-24-004303.txt : 20240311 0001214659-24-004303.hdr.sgml : 20240311 20240311103507 ACCESSION NUMBER: 0001214659-24-004303 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240307 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boyd Peter E. CENTRAL INDEX KEY: 0001739816 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38599 FILM NUMBER: 24736920 MAIL ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc. CENTRAL INDEX KEY: 0001398733 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208623253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-941-1900 MAIL ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: MonoSol Rx, Inc. DATE OF NAME CHANGE: 20070507 4 1 marketforms-64689.xml PRIMARY DOCUMENT X0508 4 2024-03-07 0001398733 Aquestive Therapeutics, Inc. AQST 0001739816 Boyd Peter E. C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE WARREN NJ 07059 false true false false See Remark 0 Common Stock 2024-03-07 4 A false 86250 0 A 245998 D Non-Qualified Stock Option (right to buy) 5.68 2024-03-07 4 A false 43125 0 A 2034-03-07 Common Stock 43125 43125 D The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. The original Form 4, filed on 3/9/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares for 59,532 shares owned when in fact 59,748 shares of the Issuer's common stock were owned. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares reported as beneficially owned by the reporting person by 216 shares. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. SVP, Information Technology, Human Resources and Communications /s/ Lori Braender, as Attorney-In-Fact 2024-03-11